Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

OBJECTIVE: This study assessed how accurately patients reported their blood pressure (BP) and titrated their antihypertensive medications according to the protocol set out by the TASMIN-SR trial. DESIGN AND METHOD: The TASMIN-SR self-management intervention involved patients with above target clinic BP and stroke, diabetes, CHD or CKD, self-monitoring their BP for the first week of every month followed by implementation of an individualised self-titration schedule. 276 patients were randomised to the intervention and 226 (80%) successfully completed 2 or 3 training sessions. Patients were followed up for 12 months and during this time submitted written records of home BP readings, and details of any medication changes made, on a monthly basis. BP readings were downloaded from each patient's monitor at 6 and 12 month follow-up clinics and these were compared to those submitted along with an assessment of protocol fidelity. RESULTS: Of 226 patients who were successfully trained, 174 (77%) completed self-management. 10,038/11,684 (85.9% (95% CI, 85.3 - 86.5) of all readings submitted were reported accurately, when compared to the readings downloaded from the monitor, and 164 patients (95%) reported their readings with at least 80% accuracy. There was an average error rate of 6.7% per patient and the only characteristic affecting this was age, under 65 years compared to those above (4.5%, (95% CI 3.2 - 5.6) vs 7.7%, (95% CI 6.4 - 9.0), p 

Original publication

DOI

10.1097/01.hjh.0000491525.34594.dc

Type

Other

Publication Date

09/2016

Volume

34 Suppl 2